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The pedunculopontine nucleus (PPN) is known as the cholinergic part of the 
reticular activating system (RAS) and it plays an important role in transitions of slow 
wave sleep to REM sleep and wakefulness.  Although both exogenous and 
endocannabinoids affect sleep, the mechanism of endocannabinoid neuromodulation has 
not been characterized at cellular level in the PPN.   
In this paper we demonstrate that both neurons and glial cells from the PPN 
respond to cannabinoid type 1 (CB1) receptor agonists.  The neuronal response can be 
depolarization or hyperpolarization, while astrocytes exhibit more frequent calcium 
waves. All of these effects are absent in CB1 gene deficient mice.  Blockade of the fast 
synaptic neurotransmission or neuronal action potential firing does not change the effect 
on the neuronal membrane potential significantly, while inhibition of astrocytic calcium 
waves by thapsigargin diminishes the response. Inhibition of group I metabotropic 
glutamate receptors (mGluRs) abolishes hyperpolarization, whereas blockade of group II 
mGluRs prevents depolarization.  Initially active neurons and glial cells display weaker 
responses partially due to the increased endocannabinoid tone in their environment. 
Taken together, we propose that cannabinoid receptor stimulation modulates PPN 
neuronal activity in the following manner: active neurons may elicit calcium waves in 
astrocytes via endogenous CB1 receptor agonists. Astrocytes in turn release glutamate, 
that activates different metabotropic glutamate receptors of neurons and modulate PPN 









The pedunculopontine nucleus (PPN) is thought to play an important role in the 
transitions of slow wave sleep (SWS) either to wakefulness or to rapid eye movement 
(REM) sleep, as increased activity of this nucleus was observed in wakefulness and REM 
sleep (Garcia-Rill, 1991, 2011; Reese et al., 1995; Winn, 2006).  The PPN is a part of the 
reticular activating system and is known as one of the main sources of the cholinergic 
fibers (Maloney et al., 1999; Jenkinson et al., 2009). 
Besides the cholinergic neurons, the PPN is also composed of non-cholinergic 
cells, which are mostly GABAergic and glutamatergic.  Several cholinergic and 
GABAergic neurons of the nucleus show synchronicity with the slow wave cortical 
activity: the majority of the cholinergic neurons fire synchronously with the ’up’ state, 
known as the active component; whereas certain non-cholinergic cells are active during 
the ’down’ state.  Parallel with the cortical gamma-activity, most of the cholinergic cells 
increase their firing rate, while non-cholinergic cells increase, decrease or do not change 
their firing rate (Mena-Segovia et al., 2008, Ros et al., 2010).  
 Endocannabinoids have multiple effects on brain functions via modulating several 
signaling processes and synaptic connections (Katona and Freund, 2012). Among several 
other effects, CB1 receptor stimulation is able to modify the sleep-wake cycles.  Early 
studies indicated that REM sleep duration and the eye movement activity is affected in 
marijuana smokers (Feinberg et al., 1975).  In vivo animal experiments revealed that the 
prototypic endocannabinoid anandamide injected intracerebroventricularly or directly to 
the PPN reduced wakefulness and increased both SWS and REM sleep.  As CB1 receptor 
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antagonists are able to reverse the effect of anandamide on sleep, it was hypothesized that 
the sleep modulation of the endocannabinoids is taking place via CB1 receptors (Murillo-
Rodriguez, 2008; Murillo-Rodriguez et al., 2008; Herrera-Solís et al., 2010).   
 Besides the well described presynaptic inhibition of neurotransmitter release by 
activation of CB1 receptor (Katona et al., 1999; Wilson and Nicoll, 2001; Kawamura et 
al., 2006), there is a growing body of evidence suggesting that astrocytes also possess 
CB1 receptors and have a role in endocannabinoid signaling.  Astrocytic CB1 receptors 
were shown in the cerebellum and the spinal cord (Hegyi et al., 2009, 2012; Rodriguez-
Cueto et al., 2013).  Furthermore, it was recently demonstrated that hippocampal 
astrocytes are directly activated by cannabinoid receptor agonists and modify synaptic 
neurotransmission by releasing gliotransmitters, i.e. glutamate (Navarrete and Araque, 
2008, 2010; Han et al., 2012; Min and Nevian, 2012; Coiret et al., 2012).   
 Despite of its potential importance, to our knowledge, no data exist about the 
cellular actions of exogenous or endocannabinoids in the PPN.  In this work, the effects 
of CB1 receptor agonists on the cells of the PPN were investigated.  We showed that 
neurons of the PPN respond in a heterogeneous way to CB1 receptor stimulation. This 
response is due to the direct activation of astrocytes and their consequential glutamate 
release, which can either depolarize or hyperpolarize PPN neurons via different 
metabotropic glutamate receptors.   
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Experiments were performed in an artificial cerebrospinal fluid (aCSF) of the 
following composition (in mM): NaCl, 120; KCl, 2.5; NaHCO3, 26; glucose, 10; 
NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1; myo-inositol, 3; ascorbic acid, 0.5; and sodium-
pyruvate, 2; pH 7.2.  For the slice preparation a modified aCSF (low Na aCSF) was used 
where 95 mM NaCl was replaced by sucrose (130 mM) and glycerol (60 mM).  All 




Animal experiments were conducted in accordance with the appropriate 
international and Hungarian laws and institutional guidelines on the care of research 
animals.  The experimental protocols were approved by the Committee of Animal 
Research of the University of Debrecen.  8-15 days old C3H mice (n = 58), as well as 
mice expressing tdTomato fluorescent proteins in a GAD2- (n = 12) or ChAT-dependent 
way (n = 17) were used from both sexes.  The floxed-stop-tdTomato (Madisen et al., 
2010; JAX mice accession number 007905), GAD2-cre (Taniguchi et al., 2011; JAX 
number: 010802) and ChAT-cre (Lowell et al., 2006; 
http://www.informatics.jax.org/reference/J:114556; JAX number: 006410) mouse lines 
were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and crossed in the 
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animal house of the Department of Physiology.  In some cases, CB1 receptor knockout 
mice (n = 9; a kind gift from A. Zimmer - Bonn, Germany) and wild type littermates (n = 
5) were also used (Zimmer et al., 1999). 
After decapitation of the animal and removal of the brain, 200 μm-thick coronal 
midbrain slices were prepared in ice-cold low Na aCSF using a Microm HM 650V 
vibratome (Microm International GmbH, Walldorf, Germany).  The slices were incubated 




Brain slices were visualized with a Zeiss Axioskop microscope (Carl Zeiss AG, 
Oberkochen, Germany).  Patch pipettes with 5 MΩ pipette resistance were fabricated, and 
filled with a solution containing (in mM): K-gluconate, 120; NaCl, 5; 4-(2-
hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES), 10; EGTA, 2; CaCl2, 0.1; Mg-
ATP, 5; Na3-GTP, 0.3; Na2- phosphocreatinine, 10; biocytin, 8; pH 7.3.  Whole-cell 
patch-clamp recordings were performed using an Axopatch 200A amplifier (Molecular 
Devices, Union City, CA, USA).  All recordings were performed on room temperature.  
Data acquisition was achieved using the Clampex 10.0 software (Molecular Devices, 
Union City, CA, USA), while data analysis was performed using the Clampfit 10.0 
(Molecular Devices) or MiniAnalysis (Synaptosoft, Decatur, GA, USA) programs.   
 
Membrane potential measurements 
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For comparing the membrane potentials two 120-second-long trace segments 
were selected: one from the control period and another starting at 3 minutes after the 
beginning of drug administration. Histograms of the membrane potential values were 
constructed from these periods and the value corresponding to the largest bin was 
considered as resting membrane potential. In those experiments where membrane 
potential changes were monitored continuously to demonstrate the time-course of the 
drug effect, the above mentioned procedure was performed at every 30 seconds of the 
trace.  
As the resting membrane potential of spontaneously firing neurons could not be 
measured, a median voltage that corresponded to the baseline potential was determined 




To activate CB1 receptors, arachidonyl–2’–chloroethylamide (ACEA) was 
administered at a concentration of 5 μM, whereas WIN55,212-2 was used in 1 μM. The 
anandamide membrane transport inhibitor, UCM707, was applied in 10 μM 
concentration.  In certain experiments, slices were continuously perfused with 10 μM 
2,3–dihydroxy–6–nitro–7–sulfamoyl-benzo[f]quinoxaline–2,3–dione (NBQX), 50 μM 
D–2–amino–5–phosphonopentanoate (D-AP5; Tocris Cookson Ltd., Bristol, UK), 1 μM 
strychnine, and 10 μM bicuculline in order to block ionotropic glutamatergic, glycinergic 
and GABAergic neurotransmissions.  In further experiments, 100 μM 7– 
(Hydroxyimino)cyclopropa[b]chrome–n–1a–carboxylate ethyl ester (CPCCOEt) and 10 
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μM 2–Methyl–6– (phenylethynyl)pyridine hydrochloride (MPEP) were used to block 
type 1 and 5 metabotropic glutamate receptors (group I mGluRs), respectively; while 10 
μM LY341495 was added to block group II mGluRs.  Spontaneous action potential firing 
was blocked by 1 μM tetrodotoxin (TTX).  In other experiments, slices were preincubated 
with 50 nM ACEA for 5-7 minutes, before the application of 5 μM ACEA. 
 
Calcium imaging 
Details of the calcium imaging were described by Kőszeghy et al. (2012).  
Briefly, for calcium imaging the acetoxymethylester form of the Oregon Green 488 
BAPTA 1 fluorescent dye (OGB; Invitrogen-Molecular Probes, Carlsbad, CA, USA) was 
used.  Slices were incubated with 33 μM OGB for 25 min (37°C, 95% O2, 5% CO2) in 
order to load the cells with the dye.   
The slices were visualized with a Zeiss Axioskop microscope (Carl Zeiss AG).  
The microscope was equipped with a fluorescent imaging system (Till Photonics GmbH, 
Gräfeling, Germany) containing a xenon bulb-based Polychrome V light source, a CCD 
camera (SensiCam, PCO AG, Kelheim, Germany), an imaging control unit (ICU), and 
the Till Vision software (version 4.0.1.3).  The excitation wavelength was set to 488 nm.  
The fluorescent filter set was composed of a dichroic mirror (Omega XF2031 
505DRLPXR; Omega Drive, Brattleboro, VT, USA) and an emission filter (LP 515, Till 
Photonics).  Throughout the calcium imaging, frames with 344 x 260 pixel resolution 
were employed with a frame rate of 10 Hz.  In parallel with the imaging, patch-clamp 
experiments were also performed.   
 11 
In order to confirm glial origin of the slow calcium waves, whole-cell patch-
clamp recordings were performed on cells displaying slow calcium waves.  These cells 
were filled with Alexa Fluor 594 (Invitrogen-Molecular Probes) for the morphological 
identification (n = 4).  Furthermore, loose-patch recordings on cells with slow calcium 
waves were also performed in some cases (n = 8, data not shown) in order to verify the 
absence of action potentials. 
In certain experiments, slices were incubated with 1 μM thapsigargin for 45 
minutes to inhibit astrocytic calcium waves in the slices. 
 
 
Visualization of the labeled neurons 
 
The neurons were filled with biocytin during the electrophysiological recordings. 
The slices accommodating the filled neurons were fixed overnight (4% paraformaldehyde 
in 0.1M phosphate buffer; pH 7.4; 4 °C). Permeabilization was achieved in Tris buffered 
saline (in mM, Tris base, 8; Trisma HCl, 42; NaCl, 150; pH 7.4) supplemented with 0.1% 
Triton X-100 and 10% bovine serum (60 min).  The slices were incubated in phosphate 
buffer containing streptavidin-conjugated Alexa488 (1:300; Molecular Probes Inc., 
Eugene, OR, USA) for 90 min.  In samples with no tdTomato expression, post hoc 
ChAT-immunohistochemistry was performed following the biocytin recovery (goat anti-
ChAT diluted 1:500; Millipore, Temecula, CA; and Texas Red rabbit-anti-goat secondary 
antibody diluted in 1:1000; Vector Laboratories Inc., Burlingame, CA, USA).  The cells 





Experiments were carried out on 3 mice expressing tdTomato in ChAT-dependent 
manner and additionally on 3 wild type C3H mice. Animals were deeply anesthetized 
with sodium pentobarbital (50 mg/kg, i.p.) and transcardially perfused with Tyrode’s 
solution (oxygenated with a mixture of 95% O2, 5% CO2), followed by a fixative 
containing 4% paraformaldehyde dissolved in 0.1 M phosphate buffer (PB, pH 7.4). After 
the transcardial fixation, the mesencephalon was removed, postfixed in the original 
fixative for 4 hours, and immersed into 10% and 20% sucrose dissolved in 0.1 M PB until 
they sank. In order to enhance reagent penetration the removed mesencephalons were 
freeze-thawed. Fifty-micrometer thick transverse sections were cut on a vibratome, and 
the sections were extensively washed in 0.1 M PB. 
A single immunostaining protocol was performed to study the cellular distribution 
of CB1-R in the PPN. Free-floating sections were first incubated in rabbit anti-CB1 
receptor antibody (diluted 1:5000; Cayman Chemical, Ann Arbor, MI) for 48 h at 4 °C, 
and then were transferred into anti-rabbit IgG conjugated with Alexa Fluor 647 (diluted 
1:1,000; Invitrogen, Eugene, OR). Before the antibody treatments the sections were kept 
in 10% normal goat serum (Vector Labs., Burlingame, California, USA) for 50 min. 
Antibodies were diluted in 10 mM TPBS (pH 7.4) containing 1% normal goat serum 
(Vector Labs., Burlingame, CA). Sections were mounted on glass slides and covered with 
Vectashield (Vector Labs, Burlingame, CA). 
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Double-immunostaining protocols were performed to study the co-localization of 
CB1-R immunoreactivity with glial fibrillary acidic protein (GFAP), a marker of 
astrocytes.  Free-floating sections were first incubated with a mixture of antibodies that 
contained rabbit anti-CB1 receptor (diluted 1:2000, Cayman Chemical, Ann Arbor, MI), 
mouse anti-GFAP (diluted 1:1,000; Millipore, Temecula, CA).  The sections were 
incubated in the primary antibody solutions for 2 days at 4 °C and were transferred for an 
overnight treatment into the appropriate mixtures of secondary antibodies that contained 
goat anti-rabbit IgG conjugated with Alexa Fluor 647 (diluted 1:1000; Invitrogen, 
Eugene, OR) and goat anti-mouse IgG conjugated with Alexa Fluor 488 (diluted 1:1000; 
Invitrogen, Eugene, OR). Before the antibody treatments the sections were kept in 10% 
normal goat serum (Vector Labs., Burlingame, CA) for 50 min. Antibodies were diluted 
in PBS (pH 7.4) containing 1% normal goat serum (Vector Labs., Burlingame, CA). 
Sections were mounted on glass slides and covered with Vectashield (Vector Labs, 
Burlingame, CA). 
Series of 1 µm thick optical sections with 500 nm separation in the z-axis were 
scanned with an Olympus FV1000 confocal microscope. Scanning was carried out using 
a 60x PlanApo N oil-immersion objective (NA: 1.42) and FV10-ASW software 
(Olympus). The scanned images were processed with Adobe Photoshop CS6 software. 
Confocal settings including confocal aperture, laser power, gain, offset and pixel size 
were identical for all scans. By filtering the background staining out with a high-pass 
intensity filter, threshold values were set for both CB1-R and the other markers. 
The specificity of the primary antibody against CB1 receptor (Cayman Chemical, 
Ann Arbor, MI) has extensively been characterized previously, using knockout control 
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(Hegyi et al, 2009). To test the specificity of the immunostaining protocol, free-floating 
sections were incubated according to the immunostaining protocol described above with 
primary antibodies omitted or replaced with 1% normal goat serum. No immunostaining 
was observed in these sections.   
For quantitative analysis of co-localization of CB1-R- and GFAP-immunopositivity, 
free-floating sections were first incubated with a mixture of antibodies that contained 
rabbit anti-CB1-R (1:2000, Cayman Chemical), goat anti-ChAT (1:500, Millipore) and 
mouse anti-GFAP (1:1000, Millipore).  The sections were first incubated in the primary 
antibody solutions for 2 days at 4 °C, followed by a treatment with an appropriate 
mixtures of secondary antibodies that were selected from the following: donkey anti-
rabbit IgG conjugated with Alexa Fluor 555 (1:1000, Invitrogen), donkey anti-goat IgG 
conjugated with Alexa Fluor 488 (1:1000, Invitrogen), and donkey anti-mouse IgG 
conjugated with Alexa Fluor 647 (1:1000, Invitrogen). 
The co-localization of CB1 receptor immunoreactive puncta with astrocytic (GFAP-
IR) profiles was quantitatively analyzed in the multiple stained sections. A 10x10 
standard square grid in which the edge-length of the unit square was 5 µm (the whole 
grid was 50 µm x 50 µm in size) was placed onto the regions of confocal images 
corresponding to the PPN.  CB1 receptor immunoreactive profiles over the edges of the 
standard grid were selected and examined whether they were also immunoreactive for the 
axonal or glial markers.  The quantitative measurement was carried out in three sections 
that were randomly selected from three animals.  Thus, the calculation of quantitative 
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All data are represented as mean ± SEM.  To compare the central tendency (mean 
or median) of two independent datasets, either Student’s t-test or the Mann-Whitney U-
test was used.  For comparisons involving multiple datasets, either ANOVA or Kruskal-
Wallis ANOVA on Ranks was performed, followed by an appropriate post hoc test 
(Tukey’s and Dunn’s test, respectively) to test for pairwise differences.  For the 
comparison of before and after values, either the paired form of Student’s t-test or the 
Signed Rank Test was used.  
Parametric and nonparametric tests were used as appropriate for the given dataset.  
Generally speaking, changes of the resting membrane potential showed Gaussian 
distribution and parametric tests were applied, while most other parameters, including the 
resting membrane potential or the firing frequency of calcium waves and the change of 
the latter showed non-Gaussian distribution and non-parametric tests were used.  In cases 
where the magnitude of effects caused by the application of a treatment was to be 
compared, the absolute value of the change in the parameter value was taken.  To 
evaluate the differences in the pattern of resting membrane potential changes among 
groups, neurons were grouped according to their resting membrane potential changes 
(depolarized, hyperpolarized and no change, 2 mV cutoff) and Fisher’s exact test was 
used to check the relationship between the treatment groups and the response groups, 
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used together with Bonferroni correction of the obtained p values when pairwise 
comparisons were done.  A similar approach was used for used for frequency changes 
with a cutoff of 0.5 Hz.  General correlation between datasets was evaluated using 
Spearman’s correlation coefficient (S).  For all tests p values below 0.05 were accepted as 
significant.  When Bonferroni correction was applied, the corrected p values are given.  
Calculations were done using the statistical module SigmaPlot 12 (Systat Software, San 





CB1 receptor activation evokes heterogeneous response in PPN neurons.  
Whole-cell patch-clamp recordings were performed in order to characterize the 
effects of CB1 receptor stimulation on the membrane potential and the firing pattern of 
the PPN neurons (n=46).  The location of the cells was confirmed and their 
morphological characteristics were revealed with biocytin labeling. All cells were located 
dorsally from the superior cerebellar peduncle in its vicinity (within 100 μm), and 
medially from the lateral lemniscus, both from the pars compacta and pars dissipata 
(Fig.1a-i). In some cases, neurons were identified by tdTomato fluorescent protein 
expressed in a ChAT- or GAD65-dependent way (Fig.1d-i). The average resting 
membrane potential of the recorded neurons was -57.4 ± 1.3 mV. However, 54% of the 
neurons fired action potentials spontaneously, with an average rate of 1.85 ± 0.35 Hz; the 
baseline potential for these spontaneously active cells were -53.6 ± 1.75 mV (n=25).   
Cells responded to 5 μM ACEA in different ways: some depolarized and 
increased action potential firing frequency; others hyperpolarized, reduced firing 
frequency or stopped completely (Fig.1j-k, Suppl. Fig. 1).  The remaining cells showed 
minimal or no response.  PPN neurons from CB1 receptor deficient mice (n = 13) showed 
smaller membrane potential alterations when compared to control animals (Fig.1k)  
In order to exclude bias originating from spontaneous fluctuations of the neuronal 
resting membrane potential and firing rate, we analyzed 13 neurons where we had at least 
7 minutes recording in naCSF without drug application.  In these cases, the membrane 
potential and firing rate values from the last 2 minutes were compared to the values taken 
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from the first 2 minutes of these traces.  The magnitude of spontaneous resting membrane 
potential fluctuations proved significantly smaller (1.031 ± 0.183 mV vs 4.322 ± 0.477 
mV in control; p<0.001; Suppl. Fig.2a) than changes of the same parameters after 5mM 
ACEA.  Neurons from CB1 knockout mice showed similarly small changes of the resting 
membrane potential (magnitude of resting membrane potential fluctuations: 0.838 ± 
0.243 mV, p<0.0001 vs control, p>0.9999 vs no treatment).  In 4 further cases, membrane 
potential and action potential firing rate were recorded for 10 minutes under control 
conditions, and the membrane potential and firing rate of the first and last minute of the 
trace were compared.  The average change of the resting membrane potential was 2 ± 
0.52 mV, whereas the average change of the firing rate was 0.52 ± 0.19 Hz.   
Another cannabinoid receptor agonist, WIN55,212-2 (1 µM; n = 16) and the 
anandamide membrane transport inhibitor UCM707 (10 μM; n = 13) also elicited a 
similar effect.  No significant differences could be revealed between the effects of the 
three applied CB1 receptor agonists on the pattern of resting membrane potential (p = 
0.7308) or firing frequency changes (p = 0.6611 for multi-group comparison; Suppl. Fig. 
2b-c). 
In an additional set of neurons, voltage-clamp experiments (n = 28) were also 
performed in order to confirm the results obtained with current clamp recordings.  At -60 
mV holding potential, 5 µM ACEA elicited an inward current in 11 cases (-24.5 ± 4.4 
pA), outward current in 7 cases (19 ± 1.9 pA) and failed to change the holding current in 
10 further cases (data not shown).   
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This heterogeneity of the observed response can potentially depend on the 
neuronal type.  Therefore, tdTomato expressing cholinergic and GABAergic neurons 
were patched.  Both cell groups exhibited all three types of responses to ACEA 
application; however, the proportions of the responses were different.  Cholinergic cells 
were depolarized, hyperpolarized or lacked response in similar proportions, whereas the 
majority of the GABAergic neurons were depolarized (Fig.2a-b).  Four out of the 9 
neurons identified as cholinergic displayed stronger depolarization than 2 mV, 2 
hyperpolarized stronger than 2 mV and membrane potential changes did not exceed 2 mV 
in 3 further cases.  7 from the 10 non-cholinergic neurons were depolarized and 3 were 
hyperpolarized. 
Blockade of the neuronal activity by 1 µM TTX or inhibition of fast synaptic 
neurotransmission by a cocktail composed of NBQX (10 µM), D-AP5 (50 µM), 
strychnine (1 µM) and bicuculline (10 µM) did not change the effects of ACEA on 
resting membrane potential significantly (Fig.2c-d).  The blocking cocktail, however, 
completely abolished spontaneous (n = 6) and evoked postsynaptic currents (n = 13). 
In the next series of experiments slices were preincubated with group I or group II 
mGluR antagonists; 10 µM MPEP and 100 µM CPCCOEt, or 10 µM LY341495, 
respectively.  Interestingly, after preincubation with group I mGluR blockers neurons 
were either depolarized or unaffected by ACEA, but only a single case of small 
amplitude hyperpolarization was observed (Fig.2e).   
In contrast to group I mGluR blockers, after the preincubation with the group II 
mGluR inhibitor LY341495 application of ACEA either caused robust hyperpolarization, 
no effect or, in a few cases, depolarization with small amplitude (Fig.2f).   
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Finally, when using blockers of the fast synaptic neurotransmission together with 
group I and II mGluR antagonists, application of ACEA resulted in no significant change 
of the resting membrane potential or firing frequency in the recorded neurons (Fig.2g). 
 
Activation of CB1 receptors alters astrocyte calcium wave frequency 
Since, blockade of fast synaptic transmission and action potential firing did not 
abolish the cannabinoid induced neuronal membrane potential changes; we tested 
whether activation of astrocytes via CB1 receptors may be influencing neuronal activity. 
Slices were loaded with OGB calcium sensitive dye, and changes of the fluorescence 
intensity were detected.  First we wanted to confirm that in accordance with our previous 
results in the cochlear nucleus (Kőszeghy et al., 2012), and with the findings of other 
authors in the cortex (Nimmerjahn et al., 2004.), cells exhibiting slow calcium waves in 
the PPN are glia. Whenever whole-cell (n = 4) or loose-patch (n = 8; data not shown) 
recordings were performed from cells producing slow calcium waves action potential 
discharge was never observed and the characteristic astrocyte morphology was revealed 
after loading the cells with Alexa 594 fluorescent dye (Fig.3a-d). Furthermore, slow 
calcium waves were detectable in the presence of TTX but disappeared when applying 
thapsigargin (see Fig.4e-f) 
In the following experiments neuronal and glial activity was monitored 
simultaneously: a neuron was patched in the OGB loaded slice in current clamp 
configuration, and calcium wave changes were detected on 5-21 loaded astrocytes within 
50 µm from the soma of the patched neuron.  
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Depolarization exceeding 2 mV in the patched neuron, was accompanied by an 
increase of astrocytic calcium wave frequency (Fig. 3e) that either preceded (Fig. 3f) or 
appeared parallel with the onset of neuronal depolarization. Surrounding astrocytes in 
these cases had initially low frequency spontaneous activity that increased rapidly after 
application of ACEA, and this two-fold increase existed for approximately 4 minutes 
(Fig. 3f).  
Astrocytes in the vicinity of neurons that were hyperpolarized upon ACEA 
application also showed an initially low basal calcium wave frequency, which increased 
during ACEA administration slightly preceding the neuronal hyperpolarization.  Calcium 
wave frequency increase in this case was not transient but kept increasing gradually and 
reached a higher value than the maximum frequency of astrocytes around depolarizing 
neurons (Fig.3g-h)  
Interestingly, initial astrocytic calcium wave frequency was high around neurons 
that were unaffected by ACEA and calcium wave frequency increase in these astrocytes 
was not detectable during the application of ACEA (Fig. 3i-j) 
 
CB1 receptors, located on astrocytes, are responsible for neuronal membrane potential 
changes upon ACEA application  
In order to prove that CB1 receptors are located on astrocytes of the PPN we 
performed immunocytochemistry to demonstrate co-localization of CB1 receptor and 
glial fibrillary acidic protein (GFAP), a marker for astrocytes. We found that a substantial 
proportion of astrocytic processes showed immunostaining for CB1 receptor (Fig. 4a-c). 
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To provide functional evidence that CB1 agonists were activating astrocytes 
directly through these CB1 receptors, we repeated the combined Ca-imaging and patch-
clamp experiments on CB1 knockout mice. Compared to wild type animals, loaded 
astrocytes showed spontaneous calcium waves at a significantly lower initial frequency.  
When ACEA was applied, the frequency did not increase significantly (Fig.4d,h). 
Neurons of the PPN in these animals (n = 13) failed to produce significant membrane 
potential change during the application of ACEA (see Fig. 1k)  
Apart from the direct activation of glial CB1 receptors, astrocytic activation might 
also occur via indirect mechanisms initiated by altered neuronal activity.  To test this 
possibility, tetrodotoxin (TTX) was applied to suspend neuronal action potential firing in 
slices from wild type mice.  In the presence of TTX calcium wave frequency in loaded 
astrocytes was significantly lower than in control conditions (Fig. 4e,h).  However, when 
ACEA was applied, a significant increase of calcium wave frequency was observed. 
(Fig.4h). 
Next, we wanted to test whether silencing of astrocytes can prevent neuronal 
membrane potential changes in response to CB1 receptor agonists. Slices from wild type 
mice were incubated with thapsigargin (1 µM), a drug depleting intracellular calcium 
stores (Navarrete and Araque, 2008, 2010), for 45 minutes prior to the 10-minute-long 
registration.  Intracellular calcium concentration of the patched neuron was set by the 
pipette solution. After preincubation with thapsigargin, as expected, no astrocytic slow 
calcium waves were observed (n = 58; Fig. 4f,h) and neuronal responses to ACEA were 
limited to negligible hyperpolarization or did not show changes (n = 7; Fig. 4g). The 
pattern of resting membrane potential change in response to ACEA application was 
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significantly different compared to control conditions (Fig.4g).  The lack of neuronal 
response was not related to the general inhibition of the neuron by thapsigargin, since 
application of 10 µM glutamate resulted in 9.43 ± 4.9 mV depolarization and 1.64 ± 1.05 
Hz increase of the firing frequency (n = 4; not shown). 
 
Effect of CB1 agonists depend on basal neuronal and glial activity 
In the next set of experiments we analyzed why membrane potential changes are 
missing in some neurons during ACEA application (see Fig.3i-j) and if this absence of 
response is related to the basal activity of neurons. We found, that the magnitude of the 
response to ACEA was inversely proportional to the initial firing frequency: larger 
changes of membrane potential were associated with lower initial firing frequencies (or 
no firing) while membrane potential of cells exhibiting high initial firing rate was almost 
unaffected by ACEA (Fig.5a).  Similarly, glial cells with originally low calcium wave 
frequency displayed a higher frequency increase to ACEA (Fig.5b). 
One possible explanation for this inverse relationship could be that a locally increased 
endocannabinoid tone prevents the action of ACEA. Thus, we incubated the slices with a 
lower concentration of ACEA (50 nM) for 5-7 minutes before application of 5 µM 
ACEA. Under these conditions changes of neuronal resting membrane potential were 
significantly lower (n = 15; Fig.5c-d). Initial astrocyte calcium wave frequency was 
higher than in control conditions (i.e. without the low concentration of ACEA, see Fig.3e 
and g). Similarly to astrocytes surrounding the non-responding neurons (see Fig.3i), 
spontaneously active loaded astrocytes incubated with 50 nM ACEA did not increase 
their calcium wave frequency to the further application of 5 µM ACEA (F
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Finally, evidence was sought whether, similarly to synthetic cannabinoid agonist 
application, endocannabinoid release from the spontaneously or otherwise discharging 
neurons can lead to astrocyte calcium wave frequency increase.  In parallel with a 10 mV 
depolarization (30 s period) of neurons (n = 3) from wild type animals astrocytes within 
50 µm from the neuronal soma almost doubled their calcium wave frequency (Fig. 6a-c).  
In case of neurons from CB1 receptor knockout animals (n = 4) this change in the 





In this study we present evidence that cannabinoids have an indirect 
heterogeneous effect on PPN neurons.  The mechanism requires the presence of 
astrocytes with functional CB1 receptors.  Summarizing our results, we propose the 
following scheme of endocannabinoid modulation within the PPN. Neurons that are 
spontaneously or otherwise active synthesize and release endocannabinoids that activate 
neighboring astrocytes via CB1 receptors.  This activation leads to consequential 
gliotransmitter release, in this particular case, glutamate.  The released glutamate will 
depolarize PPN neurons with group II mGluR receptors and hyperpolarize the ones that 
express group I mGluRs (Fig. 7).  
 
Activation of CB1 receptors on astrocytes leads to modulation of neuronal activities in 
the PPN.  
It is a well-accepted fact that astrocytes are able to modulate neuronal functions 
effectively (Perea et al., 2009; Frank, 2013.)  They possess several functional 
neurotransmitter receptors through which they can be activated in a specific way and 
release several gliotransmitters, such as glutamate, ATP, adenosine, TNFα, peptides 
(Volterra and Bezzi, 2002).  Astrocytes, for example, directly contribute to sleep 
homeostasis (reviewed by Frank, 2013) via the release of IL-1, TNFα, neurotrophins and 
prostaglandins.  One of the most extensively investigated gliotransmitter, glutamate, is 
released by astrocytes in multiple ways: besides calcium-dependent exocytosis (Parpura 
et al., 1994; Bezzi et al., 2004), reversal of uptake by plasma membrane glutamate 
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transporters (Szatkowski et al., 1990), cystine-glutamate antiport (Warr et al., 1999), 
functional unpaired connexon/pannexon "hemichannels" (Cotrina et al., 1998; Ye et al., 
2003), ionotropic purinergic receptors (Duan et al., 2003), organic anionic transporters 
(Rosenberg et al., 1994) and cell swelling induced anion channel opening (Pasantes 
Morales and Schousboe, 1988) were also reported.   
Several studies revealed that both cultured astrocytes (Molina-Holgado et al., 
2003, Stella, 2004, Walter and Stella, 2003) and astrocytes of certain brain regions, such 
as the nucleus accumbens, cingulate cortex, medial forebrain bundle, amygdala, spinal 
cord and hippocampus (Rodríguez et al., 2001; Moldrich and Wenger, 2000; Salio et al., 
2002; Navarrete and Araque, 2008; Hegyi et al., 2009) possess CB1 receptors and 
respond to cannabinoids with calcium waves (Navarrete and Araque, 2008).  The 
presence of functional CB2 receptor on astrocytes is also well established (e.g. 
Fernandez-Ruiz et al, 2008), but the contribution of this receptor to the effects observed 
by us is not likely for two reasons: ACEA is thought to be highly selective to CB1 
receptor (Hillard et al, 1999) and the effects of ACEA and WIN55,212-2 were almost 
completely absent on CB1 receptor knockout mice. 
The role of astrocytes in cannabinoid signaling of the hippocampus and barrel 
cortex was recently demonstrated (Navarrete and Araque, 2008, 2010; Min and Nevian, 
2012; Han et al., 2012; Coiret et al., 2012; Castillo et al., 2012).  In these regions 
increased neuronal activity leads to endocannabinoid release that activates astrocytes that 
respond by releasing glutamate.  Glutamate can either potentiate glutamatergic synapses 
or initiate long term depression in NMDA receptor or presynaptic mGluR dependent 
ways.  In this present work, we provide the first evidence that a similar, although not 
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identical mechanism is also present in a subcortical nucleus of the reticular activating 
system.  We showed that –similar to the cortical structures (Navarrete and Araque, 2008, 
2010; Castillo et al., 2012)- activation of neurons lead to the consequential activation of 
the astrocytes, mostly via CB1 receptor and that astrocyte activation leads to glutamate 
release, which acts on metabotropic glutamate receptors.  However, in case of the system 
that we revealed potentiation of the EPSCs by astrocytic glutamate release does not seem 
to be the main factor altering membrane potential of neurons of the PPN, as blockade of 
ionotropic glutamate receptors failed to cause significant changes in the effect of CB1 
receptor stimulation on neuronal membrane potential.   
 
The role of mGluRs in glia-neuron signaling.  
Our pharmacological tests with blockers of group I and II mGluRs suggest that 
hyperpolarization is due to the activation of postsynaptic group I mGluRs, whereas 
depolarization depends on group II mGluRs.  Recent studies demonstrated the presence 
and function of group I and II mGluRs in certain midbrain regions (Wilson-Poe et al., 
2013; Kohlmeier et al., 2013) and activation of astrocytes leading to consequential 
stimulation of presynaptic mGluRs and contribution to long term potentiation in the 
hippocampus (Navarrete et al., 2012) has also been described.  However, to the best of 
our knowledge, this study is the first that indicates indirect stimulation of different classes 
of postsynaptic mGluRs by activation of astrocytic CB1 receptors in the midbrain.  
Metabotropic glutamate receptors are present in a wide variety of locations in the 
central nervous system; where they are also present in both pre- and postsynaptic 
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locations and on astrocytes as well (e.g. Ferraguti and Shigemoto, 2006; Niswender and 
Conn, 2010).   
It is well established that astrocytes possess both group I and II mGluRs (Petralia 
et al., 1996; Schools and Kimelberg, 1999; Zur Nieden and Deitmer, 2006; D'Ascenzo et 
al, 2007; Pirttimaki and Parri, 2012; Ferraguti and Shigemoto, 2006; Schoepp, 2001; 
D'Antoni et al., 2008), making astrocytes able to sense changes of extracellular glutamate 
(Zur Nieden and Deitmer, 2006).  Glutamate and group I and II mGluR agonists elicited 
calcium signals in rat hippocampal astrocytes, inducing "glutamate-induced glutamate 
release" (Bezzi et al., 2004; Zur Nieden and Deitmer, 2006; Pirttimaki et al, 2011; 
D'Ascenzo et al, 2007).  In contrast, blockers of group I and II mGluRs failed to change 
parameters of spontaneous calcium oscillations in mouse hippocampal astrocytes (Nett et 
al, 2002).   
Several authors referred that activation of postsynaptic group I and II mGluRs 
lead to changes of the neuronal membrane potential.   
According to numerous studies, activation of postsynaptic group I mGluRs cause 
depolarization and group II mGluR stimulation leads to hyperpolarization (see Sherman, 
2014).  Group I mGluR stimulation depolarized neurons (Libri et al., 1997; Partridge et 
al, 2014) via activation of L-type calcium channel on CA1 pyramidal cells (Kato et al, 
2012) and in the cingulate cortex (Zhang and Seguela, 2010), or a non-selective cationic 
conductance on olfactory granule cells (Smith et al., 2009).  Activation of group II 
mGluRs either suppress L-type calcium channel (Chavis et al, 1994; 1995) or activate 
potassium channels (Knoflach and Kemp, 1998; Irie et al, 2006; Hermes and Renaud, 
2011), thus hyperpolarizing the neurons expressing them. 
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However, the opposite effects were also observed.  In cortical and subcortical 
structures (hippocampus, amygdala, olfactory bulb, pallidum, laterodorsal tegmental 
nucleus) stimulation of postsynaptic mGluR5 (belonging to the group I mGluRs) lead to 
the activation of K+ channels (Jian et al., 2010; Mannaioni et al., 2001; Poisik et al, 2003; 
Rainnie et al., 1994; Harata et al., 1996; Kohlmeier et al. 2013), which hyperpolarized the 
neurons expressing the receptor.  Activation of group II mGluRs in somatodendritic 
location caused a postsynaptic excitatory response in hippocampal CA3 pyramidal cells 
by activating a cationic conductance and inhibiting a potassium conductance (Ster et al., 
2011).   
In our project, blockers of group I mGluRs prevented ACEA-induced 
hyperpolarization and the group II. mGluR antagonist inhibited depolarization.  Blockade 
of ionotropic glutamate receptors failed to change the effect of ACEA on the resting 
membrane potential, whereas glutamate was capable of causing neuronal depolarization 
in the presence of thapsigargin.  These results indicate that astrocytic activation by CB1 
receptor agonists, different groups of metabotropic glutamate receptors and neuronal 
responses to glutamate are important for the observed multiple effects of cannabinoids.  
Based on our data, the simplest model is where endocannabinoids released by neurons 
activate astrocytes via the CB1 receptor.  Astrocytes, in turn, release glutamate and 
depolarize or hyperpolarize surrounding neurons by activating different groups of 
mGluRs on them (Fig. 7).   
However, the proposed model might oversimplify the situation.  Astrocytes are 
known to express different mGluRs (Zur Nieden and Deitmer, 2006) leading to 
functional differences between astrocytes based on the presence or absence of certain 
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mGluRs (Parri et al, 2010).  We observed differences in the time scale and magnitude of 
astrocytic response to ACEA around depolarized and hyperpolarized neurons (Fig. 3f, h).  
This might indicate that distinct groups of astrocytes have different mGluRs, which could 
be responsible for prolongation of glutamate actions by "glutamate-induced glutamate 
release" (D'Ascenzo et al, 2007), increase or decrease of tonic glutamate release (Xi et al, 
2002; Zur Nieden and Deitmer, 2006), or release of glutamate co-released with another 
gliotransmitter from different groups of astrocytes (Shibasaki et al, 2014). 
We also showed that an increased endocannabinoid tone may be responsible for 
the absence or reduction of neural and astrocytic response to ACEA. However, other 
activity-dependent or cell type specific mechanisms might also be responsible for this 
later phenomenon, as preincubation of slices with low dose of ACEA could not mimic 
fully the non-responsiveness of cells with initially high activity level. 
 
The heterogeneous response of PPN neurons to CB1 receptor stimulation might 
contribute to the reported effects of exogenous and endocannabinoids on sleep. 
Cannabinoid receptor agonists are known to increase the duration of REM sleep 
(Murillo-Rodriguez et al., 1998, 2001, 2008; Murillo-Rodriguez, 2008; Herrera-Solís et 
al., 2010) and non-REM sleep (Herrera-Solís et al., 2010; Bolla et al., 2008).  Although 
correlating our in vitro data with in vivo observations might be speculative, we believe 
that the modulatory effect of endocannabinoids on PPN neurons, reported in this paper, 
might contribute to physiological and pathophysiological mechanism through which, 
endo- and exogenous cannabinoids increase REM and non-REM sleep duration (Feinberg 
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et al., 1975; Murillo-Rodriguez et al., 1998, 2008; Murillo-Rodriguez, 2008; Herrera-
Solís et al., 2010).   
In correlation with cortical slow wave activity, the majority of cholinergic cells 
fire at the active phase, whereas a subset of non-cholinergic cells discharges during the 
inactive phase.  When cortical gamma activity is present, the majority of cholinergic 
neurons increase firing rate and only a fast firing minority lack changes, whereas certain 
subgroups of non-cholinergic neurons increase, decrease or do not change their firing rate 
(Mena-Segovia et al., 2008; Ros et al., 2010).  In line with the above, our study revealed 
similar cell type specific differences of the cannabinoid effect.  Although both 
cholinergic and GABAergic cells showed all three types of responses, a substantial part 
(one-third) of the cholinergic neurons did not respond to CB1 receptor stimulation.  
These neurons all had relatively high initial firing frequency (4-6 Hz), indicating that they 
might belong to the group of "fast-firing cholinergic" cells (Mena-Segovia et al., 2008), 
which do not increase firing rate during cortical gamma activity.  Depolarization, on the 
other hand, dominated (70%) among the GABAergic cells. Interestingly, in vivo 
observations showed that a proportion of non-cholinergic neurons with quiescent and 
irregular firing pattern were activated in time with cortical gamma oscillations, whereas 
neurons with tonic firing pattern did not change (Ros et al., 2010).  It is possible, that the 
majority of our GABAergic cells belong to these quiescent or irregular cells observed by 
Ros et al. (2010). The single GABAergic neuron in our sample that showed tonic activity 
with a higher firing rate did not respond to ACEA.   
Although the PPN also contains glutamatergic neurons, we did not investigate this 
population.  However, based on the similarities between the GAD65-positive and non-
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cholinergic populations –which theoretically includes both GABAergic and glutamatergic 
neurons-, one can assume that glutamatergic neurons might have a response similar to 
that of the GABAergic ones. 
Based on the in vivo data, one might hypothesize that REM sleep associated with 
cortical desynchronization (e.g. Pace-Schott, 2009; Steriade et al., 1990) requires an 
increased firing rate from the majority of cholinergic cells and a subset of GABAergic 
cells, along with inhibition of a small population of irregular firing GABAergic neurons, 
while fast firing cholinergic and tonic firing GABAergic neurons do not change their 
activity (Mena-Segovia et al., 2008; Ros et al., 2010). In contrast with these expectations, 
our findings show that only one-third of the cholinergic neurons were activated by 
ACEA, while the other two-thirds were hyperpolarized or lacked response to CB1 
receptor stimulation.  The majority of the GABAergic neurons were activated by ACEA 
and only a minor population lacked response or became hyperpolarized.   
This contradiction may be explained in several ways.  First, according to some studies 
(Murillo-Rodriguez et al., 2001; Herrera-Solís et al., 2010; Bolla et al., 2008) 
cannabinoids increased the duration of both REM- and non-REM sleep; thus, it might be 
the case that depending on the actual combination of PPN neuronal responses, different 
phases of sleep will be effected by cannabinoids.  Second, it is well established that the 
proportion of REM- and non-REM sleep from the total duration of sleep is changing with 
age (Tarokh and Carskadon, 2009).  In rats, it reaches its maximum around the 10th 
postnatal day, and shows a gradual decrease until the proportion characteristic for 
adulthood is established around the 30th postnatal day.  These changes are concomitant 
with changes of membrane potential by stimulation of different receptors (NMDA, 
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kainate, M2, GABAA and B, 5-HT1, etc.; reviewed by Garcia-Rill et al., 2008).  Age-
related changes of the expression level of CB1 receptor and metabotropic glutamate 
receptors were also shown in other structures (e.g. Hubert and Smith, 2004; Díaz-Alonso 
et al, 2014).  Therefore, the conditions we explored can be applicable for younger ages 
characterized by an increased REM sleep duration.   
Finally, our in vitro approach investigates a network that lacks important 
modulating input and the influence of global brain activity. Thus neurons in this slice 
preparation most likely reflect the first step in the complex modulating effects of 
cannabinoids that may look different in the complete system. Nevertheless, this approach 
is ideal for dissecting the pharmacological interplay between cellular elements of the 
PPN. 
 
In summary, we provided evidence that PPN neurons change their membrane potential 
and action potential firing frequency in a heterogeneous way to CB1 receptor stimulation, 
via activation of astrocytic CB1 receptors. This indirect cannabinoid signaling pathway 
seems to regulate the PPN neurons effectively, and most likely provides an important 
contribution to its oscillatory activity determining global brain states.   
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Fig. 1.  The CB1 receptor agonist ACEA elicits heterogeneous responses on PPN 
neurons.  a. Schematic drawing of a coronal midbrain slice (based on Paxinos, 2004).  
The area of panel b is indicated by a black square. (PPN = pedunculopontine nucleus, 
LDTg = laterodorsal tegmental nucleus, LDTgV = laterodorsal tegmental nucleus, ventral 
part)  b. Micrograph illustrating the distribution of tdTomato-expressing cholinergic 
neurons in a 200 micron thick section of the mesencephalon.  Arrowheads are pointing to 
the PPN on both sides of the midbrain section.  Scale bar: 500 µm.  c. Drawing of a 
biocytin-labeled PPN neuron located dorsal from the superior cerebellar peduncle (scp, 
dashed line).  Scale bar: 100 µm.  d-f. Micrograph of an identified cholinergic neuron.  d. 
Biocytin labeling, e. tdTomato expressed in a ChAT-dependent way, f. merged image.  g-
i. Micrograph of an identified GABAergic neuron. g. Biocytin labeling, h. tdTomato 
expressed in a GAD65-dependent way, i. merged image.  Scale bar for d-i: 20 µm.  j. 
Representative traces of neurons responding to the CB1 receptor agonist ACEA in 
different ways: depolarization and increase of firing frequency (top), hyperpolarization 
and decrease of firing frequency (middle), lack of response (bottom).  k. Summary of all 
data obtained from wild type mice (black dots; n = 46) and from CB1 receptor knockout 
mice (red dots; n = 13).  The change of the resting membrane potential to ACEA is 
represented on the X axis while the firing frequency change is on the Y axis.   
In the preparations from wild type animals a significant correlation was found 
(S=0.599, p<0.001) between the change in membrane potential and the change in firing 
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frequency for control cells, suggesting that these processes are not random changes of the 
examined parameters but consequences of the drug application.  In contrast, only small 
changes of the membrane potential were revealed in the CB1 knockout samples (absolute 
values of change: 4.322±0.477 mV in the wild type and 0.838±0.243 mV in the 
knockout, p<0.001). Most notably, there was no significant correlation between the 
membrane potential change and the frequency change (S=-0.259, p=0.382, suggesting 
that the changes of the parameters are random fluctuations of the examined parameters. 
 
 
Fig. 2.  Cell type specific differences and pharmacological characterization of the 
cannabinoid effect on PPN neurons. Neurons responding to CB1 receptor activation 
under control conditions are represented with gray dots, while cells of a particular type or 
during application of a particular pharmacon are represented with black dots. Membrane 
potential change is indicated on the X axis while firing frequency change appears on the 
Y axis.  a. Effects of the CB1 receptor agonist ACEA in choline acetyltransferase 
(ChAT) positive (n = 12) and (b) GAD65 positive GABAergic neurons (n = 9).  c. 
Preincubation with 1 µM tetrodotoxin (TTX) did not diminish changes of the resting 
membrane potential by ACEA (n = 13) or (d) blockers of fast synaptic neurotransmission 
(10 µM NBQX, 50 µM D-AP5, 1 µM strychnine, 10 µM bicuculline) did not alter 
significantly the effect of ACEA on PPN neurons (p = 0.603 for multi-group comparison; 
n = 24).  e. ACEA application dominantly depolarized PPN neurons (n = 12) in the 
presence of group I metabotropic glutamate receptor antagonists (100 µM CPCCOEt, 10 
µM MPEP).  Under these conditions, the proportion of hyperpolarized cells was 
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significantly lower than without preincubation of group I mGluR blockers (p = 0.021).  f. 
The group II metabotropic glutamate receptor antagonist (10 µM LY341495) mostly 
prevented the depolarizing effect of ACEA (n = 10) and the overall distribution of 
membrane potential and firing frequency changes upon ACEA application were 
significantly different from that of the control condition (p = 0.0111) and from the 
preincubation with group I mGluR blockers (p = 0.0033).  g. When applied together, 
inhibitors of fast synaptic neurotransmission and mGluRs almost fully abolished the 
effect of ACEA on PPN neurons, resulting in no significant change of the resting 
membrane potential (p = 0.064) or firing frequency (p = 0.063; n = 7).   
 
 
Fig. 3.  Calcium wave frequency changes in astrocytes neighboring neurons responding 
differently to ACEA application.  a. OGB-loaded cells in a slice preparation of the PPN.  
b. Slow calcium waves recorded from the cell indicated with asterisk on panel a.  c. 
Membrane potential changes (bottom traces) of the cell labelled with asterisk in response 
to a current step protocol (top traces). Action potentials were not present even in case of 
large depolarizing current steps.  d. Fluorescent micrograph showing the morphology of 
the recorded cell.  e. Neuronal depolarization and increase of firing frequency elicited by 
ACEA (upper trace) accompanied by increased frequency of calcium waves in the 
neighboring astrocytes (lower traces).  f. Time course of the neuronal membrane potential 
(top) and astroglial calcium wave frequency (bottom) changes. Each data point represents 
the average of 30 seconds.  The dashed lines indicate the average of all data points before 
the application of ACEA Note that the significant increase of astrocytic calcium event 
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frequency preceded neuronal depolarization, reached a plateau after 1-2 minutes and 
existed for approximately 4 minutes.  The maximal frequency of astrocytic calcium 
waves during application of ACEA was 0.93 ± 0.27/min (n = 7).  g-h. Astrocytes in the 
vicinity of neurons hyperpolarizing to ACEA also increased their calcium wave 
frequency, which happened parallel with the neuronal membrane potential change. The 
frequency increase was more robust than in the astrocytes surrounding depolarizing 
neurons (maximal frequency: 1.5 ± 0.14/min; n = 5) and did not show decay.  i-j. 
Astrocytes around neurons that did not respond to ACEA showed a relatively high initial 
calcium wave frequency (1.22 ± 0.08/min) that did not change significantly (1.16 ± 
0.1/min; n = 4) during the application of the drug.  Additional dashed lines on the lower 
trace indicate the averages of astrocytic calcium wave frequencies around neurons 
responding with depolarization (a; value from panel f) or hyperpolarization (b; value 
from panel h).  
 
Fig. 4.  CB1 receptors located on astrocytes are responsible for neuronal 
membrane potential changes in response to ACEA.  a-c. Micrographs of a 1-µm-thick 
confocal optical section illustrating the co-localization between astrocyte specific GFAP 
immunostaining (a) and CB1 receptor immunolabeling for (b). Double labeled profiles on 
the superimposed image (c) are marked with arrowheads.  On average, 21.28 ± 1.91 % of 
CB1 receptor positive puncta were co-localized with GFAP-immunopositivity (624 dots 
from 3 animals). Scale bar: 5 µm.  d. Calcium level changes in three OGB-loaded 
astrocytes. The CB1 receptor agonist ACEA (5 µM) did not change the frequency of 
astrocytic calcium waves in CB1 receptor knockout mice.  e. The presence of 
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tetrodotoxin in the bath did not prevent astrocytic calcium wave frequency increase upon 
ACEA application.  f. Preincubation of thapsigargin diminishes basal astrocytic calcium 
waves, prevents their frequency increase during ACEA application and (g) significantly 
reduced neuronal membrane potential changes (p = 0.0066; n = 7; resting membrane 
potential, ΔRMP; firing frequency, ΔFreq; control conditions, grey dots; thapsigargin 
preincubation, black dot).  h. Changes of astrocytic calcium wave frequency under 
control conditions (hollow bars) and during application of ACEA (black bars). 
Considering all loaded astrocytes, in wild type animals ACEA elicited an increase of 
calcium wave frequency (from 0.57 ± 0.07/min to 0.91 ± 0.09/min; p = 0.001).  In CB1 
knockout mice, the control calcium wave frequency was significantly lower than in the 
wild type (0.24 ± 0.09/min; p = 0.0064, n = 73), and frequency increase to ACEA is not 
significant (0.27 ± 0.08/min; p = 0.39).  In the presence of TTX, in wild type animals the 
calcium wave frequency under control conditions was low (0.09 ± 0.03/min; p = 0.0004 
compared to the control in n aCSF; n = 53) and ACEA evoked a large, significant 
frequency increase (0.56 ± 0.12/min; p = 0.0001).  Thapsigargin diminishes all calcium 
waves (n = 58). 
 
 
Fig. 5.  Increased endocannabinoid tone prevents membrane potential changes in 
certain neurons.  a. The original firing frequency of the neurons (n = 46) is inversely 
proportional to the ACEA evoked membrane potential change (S = -0.8046, p = 0.019).  
b. Astrocytic calcium wave frequency change also shows an inverse relationship with the 
original frequency of astrocytic calcium waves (S = -0.8545, p = 0.0015).  c. Membrane 
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potential registration of a neuron (upper trace) and calcium waves in the neighboring 
astrocytes (three lower traces) in a slice preincubated with low concentration of ACEA 
(50 nM). Horizontal bars above the voltage trace represent the periods of application of 
ACEA in different concentrations. Note the high basal firing frequency of the neuron and 
the high basal frequency of astrocytic calcium waves.  d. Time course of the neuronal 
membrane potential (top) and astroglial calcium wave frequency (bottom) changes. Each 
data point represents the average of 30 seconds.  The calcium wave frequency of 
astrocytes preincubated with 50 nM ACEA was significantly higher (0.62 ± 0.08/min; p = 
0.0001; n = 120) than the basal calcium wave frequency of astrocytes in the vicinity of 
neurons that depolarized (b) or hyperpolarized (c) to ACEA, but significantly smaller 
than the average calcium wave frequency of astrocytes next to neurons not responding to 
ACEA (a) (n = 48, p = 0.0001).  Application of 5 µM ACEA did not elicit a significant 
further change of the calcium wave frequency (0.66 ± 0.1/min).  The dashed lines 
indicate the averages of the calcium wave frequency of astrocytes. The dashed line 
without a label belongs to astrocytes in slices preincubated with 50 nM ACEA.  e. 
Neuronal membrane potential (ΔRMP) and firing frequency (ΔFreq.) changes in response 
to 5 µM ACEA without preincubation (grey dots) and after preincubation with 50 nM 
ACEA (black dots).  Preincubation with a low dose of ACEA significantly reduced but 
did not diminish neuronal responses (p = 0.021 compared to the changes obtained 
without preincubation with low dose of ACEA; n = 15).  
 
Fig. 6.  Suprathreshold neuronal depolarization elicits calcium waves on the neighboring 
astrocytes in a CB1 receptor dependent way.  a. Patched neuron (asterisk) and OGB 
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loaded astrocytes in a PPN slice prepared from a wild type mouse. b. Action potential 
discharge (top trace) during a 10 mV depolarization of the neuron (with asterisk on panel 
A) evoked by current injection and the average of intracellular calcium concentration 
changes produced by 7 neighboring astrocytes (bottom trace). Vertical dashed lines 
indicate the period of the current pulse. c. Time course of astrocytic calcium wave 
frequency changes. Each data point represents the average of 30 seconds. The frequency 
increased significantly during neuronal depolarization (p = 0.004).  d-f. The same 
depolarization in a neuron from a CB1 knockout animal could only evoke mild calcium 
wave frequency increase in neighboring astrocytes (p = 0.058). 
 
Fig. 7.  Proposed model of endocannabinoid signaling in the PPN.  1. Active PPN 
neurons synthesize endocannabinoids (ECB). 2. Endocannabinoids activate CB1 
receptors on astrocytes.  3. Astrocytes, in turn, increase their calcium wave frequency and 
release gliotransmitters such as glutamate.  Glutamate either acts on neighboring neurons 
via activation of group I metabotropic glutamate receptors and hyperpolarizes them (4a), 
or depolarizes neurons through group II mGluRs (4b.)  Glutamate might activate 
astrocytic glutamate receptors as well (hollow green arrows).  These astrocytic mGluRs 
can possibly lead to modifications of gliotransmitter release, thus contributing to the 























































































Suppl. Fig. 1. Representative membrane potential histograms of 120-second-long traces from neurons responding to 
the CB1 receptor agonist ACEA in different ways (black columns = control, red columns = application of ACEA). a. 
Membrane potential histogram of a neuron depolarized by ACEA. b. Membrane potential histogram of a neuron 






Suppl. Fig. 2. a. Spontaneous fluctuations of the membrane potential and firing rate (black dots) and changes of the 
same parameters upon application of 5μM ACEA (gray dots; the same in panels b-c)  b. The effect of WIN55,212-2 
(1 μM) on PPN neurons (black dots)  c. Membrane potential and firing rate changes after application of anadamide 
membrane transport inhibitor UCM707 (10 μM).  Membrane potential change is indicated on the X axis while firing 
frequency change appears on the Y axis. 
 
